title: [Effect of Nuanxin Capsule on two rat models with heart failure].
abstract: OBJECTIVE
  To observe the effects of Nuanxin Capsule (NC) on the rat models of heart failure induced by abdominal aorta constriction and adriamycin.
  
  
  METHODS
  Rats were randomly divided into the following groups: model control group, low-dose and high-dose, and digoxin group. Meanwhile, the pseudo-operation and NC groups were seperately established. After treatment for 30 days, the heart rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), maximal rate of increase and decrease in left ventricular pressure (+/- dp/dt), mean peripheral blood pressure (MBP) as well as levels of serum superoxide dismustase (SOD), malondialdeh-vde (MDA), cardiac index and heart size were measured.
  
  
  RESULTS
  SBP, LVSP, +/- dp/dt and SOD activity increased,while LVEDP,serum MDA levels decreased in high and low-dose NC groups of two models. The heart rates also decreased, but the difference was insignificant (P>0.05, compared with those of model group). Besides, the heart rate,heart size and cardiac index, as well as serum Ang II levels also decreased. The differences were significant as compared with the digoxin group (P>0.05). The high-dose NC also significatly improved MBP and SOD (P<0.05 and P<0.01).
  
  
  CONCLUSIONS
  Nuanxin Capsule has good therapeutic effects on the rats models of adriamycin and abdominal aorta constriction induced heart failure.
authors: Shenzhen Institute of Otolaryngology, Shenzhen 518116, China. azhou828@163.com
authors: Cai-jie
authors: CJ
authors: Zhou
authors: Jun
authors: J
authors: Li
authors: Xue-zhen
authors: XZ
authors: Liao
authors: Hui-fang
authors: HF
authors: Liao
authors: Shuai
authors: S
authors: Wang
authors: Xiao-ping
authors: XP
authors: Lai
authors: Shu-qi
authors: SQ
authors: Qiu
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002214:Capsules; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000009:adverse effects; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006321:Heart / Q000187:drug effects / Q000503:physiopathology*; D054144:Heart Failure, Diastolic / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013482:Superoxide Dismutase / Q000097:blood; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D002214:Capsules; D004365:Drugs, Chinese Herbal; D008315:Malondialdehyde; D004317:Doxorubicin; D013482:Superoxide Dismutase